Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ebcm.2006.04.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of drug-drug interaction between rosuvastatin and tacrolimus and the risk of hepatic injury in rats.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Minde Road No. 1, Nanchang, 330006, Jiangxi, China.
Multimorbidity, therapeutic complexity, and polypharmacy, which greatly increases the risk of drug-drug interactions (DDIs) and adverse medical outcomes, have become important and growing challenges in clinical practice. Statins are frequently prescribed to manage post-transplant dyslipidemia and reduce overall cardiovascular risk in solid organ transplant recipients. This study aimed to determine whether rosuvastatin has significant DDIs with tacrolimus (the first-line immunosuppressant) and to evaluate the risk of hepatotoxicity associated with concomitant therapy.
View Article and Find Full Text PDFEnhancing the Therapeutic Effect and Bioavailability of Irradiated Silver Nanoparticle-Capped Chitosan-Coated Rosuvastatin Calcium Nanovesicles for the Treatment of Liver Cancer.
Pharmaceutics
January 2025
Department of Pharmaceutics, Faculty of Pharmacy, Nahda University, Beni Suef 62764, Egypt.
Liver cancer is a prevalent form of carcinoma worldwide. A novel chitosan-coated optimized formulation capped with irradiated silver nanoparticles (INops) was fabricated to boost the anti-malignant impact of rosuvastatin calcium (RC). Using a 2-factorial design, eight formulations were produced using the solvent evaporation process.
View Article and Find Full Text PDFA Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia.
J Clin Med
January 2025
Department of Internal Medicine, Division of Cardiology, Kangdong Sacred Heart Hospital, Seoul 05355, Republic of Korea.
This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24-48.
View Article and Find Full Text PDFPotential antihyperlipidemic effects of myrcenol and curzerene in high-fat fed rats.
BMC Pharmacol Toxicol
January 2025
Evangelical College, N'Djamena, BP 1200, Chad.
The study evaluated the anti-hyperlipidemic effects of myrcenol and curzerene on a high fat diet induced hyperlipidemia rat model. Thirty male albino rats were fed on a high-fat diet for four months. The HFD-induced hyperperlipidemia rats were treated with rosuvastatin (10 mg/kg), curzerene (130 mg/kg) and myrcenol (100 mg/kg) for four weeks.
View Article and Find Full Text PDFStatin use and dementia risk: A systematic review and updated meta-analysis.
Alzheimers Dement (N Y)
January 2025
Unlabelled: Dementia affects 55 million people globally, with the number projected to triple by 2050. Statins, widely prescribed for cardiovascular benefits, may also have neuroprotective effects, although studies on their impact on dementia risk have shown contradictory results. In this systematic review and meta-analysis, we searched PubMed, Embase, and Cochrane following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!